[Insulin autoantibodies and insulin-induced antibodies in children with insulin-dependent diabetes]

Related Experiment Video

Updated: Oct 29, 2026

Extraction of Tissue Antigens for Functional Assays
08:32

Extraction of Tissue Antigens for Functional Assays

Published on: September 10, 2012

M P Bridel1, N Tubiana-Rufi, C Levy-Marchal

  • 1Service de Diabétologie, Hôpital Robert-Debré, Paris, France.

Diabete & Metabolisme
|November 1, 1992
PubMed

Insights

In diabetic children on human insulin, anti-insulin antibodies develop quickly. Pre-existing insulin autoantibodies do not affect the development of these antibodies during treatment.

Area of Science:

  • Pediatric Endocrinology
  • Immunology
  • Diabetes Mellitus Research

Context:

  • Human insulin therapy is standard for type 1 diabetes in children.
  • Early development of insulin antibodies can impact treatment efficacy.
  • Understanding antibody kinetics is crucial for optimizing pediatric diabetes management.

Purpose:

  • To investigate the temporal development of insulin antibodies in children with diabetes undergoing human insulin therapy.
  • To assess the influence of pre-existing insulin autoantibodies on the subsequent development of insulin-binding antibodies.

Summary:

  • Anti-insulin antibodies were measured in 16 children (4-13 years) over 9 months of human insulin treatment.
  • Insulin autoantibodies were present at diagnosis in 11 children; all children developed insulin antibodies within 2 months.
  • Antibody development was rapid and frequent, irrespective of baseline insulin autoantibody status.

Impact:

  • This study highlights the rapid immunogenicity of human insulin in pediatric patients.
  • Findings suggest that routine monitoring for insulin antibodies may be warranted in children starting human insulin therapy.
  • The study provides insights into the immunologic response to insulin therapy in a vulnerable pediatric population.
Abstract

More Related Videos

Electrochemiluminescence Assays for Human Islet Autoantibodies09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-1906:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...